Ibandronate
Hypercalcemia of Malignancy
SWOG Cancer Research NetworkSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hypercalcemia of Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zoledronate SWOG Cancer Research Network | Phase 3 | BB |
Denosumab Amgen | Phase 2 | B |
Same molecule, other indications
Ibandronate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →